We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Rapid Serological Assay Developed for Strongyloidiasis

By LabMedica International staff writers
Posted on 19 Aug 2014
Print article
Image: The adult free-living female Strongyloides stercoralis with a row of eggs within the body of the nematode (Photo courtesy of the CDC - Centers for Disease Control and Prevention).
Image: The adult free-living female Strongyloides stercoralis with a row of eggs within the body of the nematode (Photo courtesy of the CDC - Centers for Disease Control and Prevention).
Several imperfect methods exist for diagnosing strongyloidiasis and stool examination with microscopic identification of larvae considered the gold standard diagnostic procedure, showing good specificity with experienced staff.

Individuals with strongyloidiasis are typically asymptomatic, and the infection can persist for decades without detection. Problems arise when individuals with unrecognized Strongyloides stercoralis infection are immunosuppressed, which can lead to hyper-infection syndrome and disseminated disease with an associated high mortality if untreated.

An international team of scientists led by those at McGill University (Montreal, QC, Canada) obtained 54 positive serum samples that were confirmed by positive stool samples for S. stercoralis from multiple reference laboratories. There were 47 negative control samples consisted of sera obtained from healthy individuals residing in Canada with no prior history of travel outside of Canada and individuals with confirmed diagnosis of other parasitic infections, including trichinosis, and were negative for Strongyloides by an “in-house” enzyme-linked immunoassay (ELISA) (NRCP).

The team developed a rapid and sensitive serodiagnostic assay for strongyloidiasis based on a 31-kDa recombinant antigen from S. stercoralis (NIE) using a novel diffraction-based optical biosensor technology. The panelPlus oligonucleotide-based addressing system was used for NIE immobilization onto dotLab Sensors and All assays were performed on the dotLab mX System using panelPlus D Sensors (Axela, Inc.; Toronto, ON, Canada). All serum samples were also tested by an NIE ELISA that was developed and validated.

The assay readily differentiated S. stercoralis-infected patients from controls detecting 96.3% of the positive cases, and with no cross reactivity observed in the control group. These results were in excellent agreement with results obtained by an NIE-based ELISA. A further 44 sera from patients with suspected S. stercoralis infection were analyzed and showed 91% agreement with the NIE ELISA. The novel, high-sensitivity diffractive optics technology (dot) platform generated results in less than 30 minutes and is fully automated requiring minimal user intervention. This makes it potentially attractive for near-patient testing and for use in regions where technical expertise or adequate laboratory facilities may not be available.

The authors concluded that with the ability to create custom multiplex assays using the panelPlus oligonucleotide-based addressing system, the dotLab mX System could also be used further to improve Strongyloides serodiagnostics by incorporating multiple recombinant antigens in a multiplex format or by simultaneously screening for clinically relevant co-infections such as Human T-cell lymphotropic virus type 1 (HTLV-1).

The study was published on August 7, 2014, in the journal Public Library of Science Neglected Tropical Diseases.

Related Links:

McGill University 
Axela Inc.


Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
ACTH Assay
ACTH ELISA
New
Immunofluorescence Analyzer
MPQuanti

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.